MX2012013375A - Peptido c pegilado. - Google Patents
Peptido c pegilado.Info
- Publication number
- MX2012013375A MX2012013375A MX2012013375A MX2012013375A MX2012013375A MX 2012013375 A MX2012013375 A MX 2012013375A MX 2012013375 A MX2012013375 A MX 2012013375A MX 2012013375 A MX2012013375 A MX 2012013375A MX 2012013375 A MX2012013375 A MX 2012013375A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- pegylated
- modified forms
- activityin
- terminus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
Abstract
La presente invención se refiere a formas modificadas de péptido C y métodos para su uso. En un aspecto, las formas modificadas del péptido C comprenden derivados de péptido C PEGilados que comprenden al menos un grupo PEG unido al extremo N, que exhiben actividad farmacocinética y biológica superior in vivo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34529310P | 2010-05-17 | 2010-05-17 | |
US201161448402P | 2011-03-02 | 2011-03-02 | |
PCT/US2011/036858 WO2011146518A2 (en) | 2010-05-17 | 2011-05-17 | Pegylated c-peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012013375A true MX2012013375A (es) | 2013-04-11 |
Family
ID=44992295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012013375A MX2012013375A (es) | 2010-05-17 | 2011-05-17 | Peptido c pegilado. |
Country Status (9)
Country | Link |
---|---|
US (2) | US8927488B2 (es) |
EP (1) | EP2571896A4 (es) |
JP (1) | JP2013533217A (es) |
KR (1) | KR20130115086A (es) |
CN (1) | CN103119055A (es) |
CA (1) | CA2798518A1 (es) |
MX (1) | MX2012013375A (es) |
NZ (1) | NZ603399A (es) |
WO (1) | WO2011146518A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0511269D0 (en) * | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
WO2011123813A2 (en) * | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
KR20130115086A (ko) | 2010-05-17 | 2013-10-21 | 세빅스 인코포레이티드 | 페길화된 c-펩티드 |
CA2848204C (en) * | 2011-09-12 | 2023-04-04 | Amunix Operating Inc. | Glucagon-like peptide-2 compositions and methods of making and using same |
CN104220086A (zh) * | 2011-11-17 | 2014-12-17 | 塞比克斯股份公司 | Peg化的c-肽 |
US9988433B2 (en) * | 2013-03-14 | 2018-06-05 | Mosaic Biosciences, Inc. | Covalent modification of biological macromolecules |
EP2822533B1 (en) | 2012-02-02 | 2021-01-20 | Mosaic Biosciences, Inc. | Biomaterials for delivery of blood extracts and methods of using same |
WO2013148579A1 (en) * | 2012-03-29 | 2013-10-03 | Cebix Inc. | Pegylated c-peptide |
US9650331B2 (en) | 2012-06-18 | 2017-05-16 | Polytherics Limited | Conjugation reagents |
AU2014328458B2 (en) * | 2013-09-24 | 2020-03-12 | Allergan Pharmaceuticals International Limited | Method of extracting protein |
JP2018507908A (ja) * | 2015-02-09 | 2018-03-22 | モザイク バイオサイエンシズ,インコーポレイティド | 分解性チオール−エンポリマー及びそれを製造する方法 |
EP3265479A4 (en) * | 2015-03-03 | 2018-11-14 | Avalon Biologics Limited | Compositions and methods for pegylated il-11 |
US10627415B2 (en) | 2015-03-12 | 2020-04-21 | Board Of Trustees Of Michigan State University | Compositions and methods for diagnosing, monitoring, and treating an autoimmune disease |
AU2016324119B2 (en) * | 2015-09-18 | 2019-11-14 | Himuka AM Australia Pty Ltd. | Long-acting adrenomedullin derivative |
CN108265044B (zh) * | 2016-12-31 | 2021-05-11 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用 |
JP7058857B2 (ja) * | 2017-08-30 | 2022-04-25 | クラシエホームプロダクツ株式会社 | 毛髪タンパク質の水との相互作用測定方法 |
JP7377195B2 (ja) * | 2017-09-29 | 2023-11-09 | ハンミ ファーマシューティカル カンパニー リミテッド | リンカーとして非ペプチド性重合体結合脂肪酸誘導体化合物を含むタンパク質結合体及びその製造方法 |
WO2019108865A1 (en) * | 2017-12-01 | 2019-06-06 | Csl Behring Llc | Methods for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation |
US20210238238A1 (en) * | 2018-05-16 | 2021-08-05 | Csl Limited | Soluble complement receptor type i variants and uses thereof |
EP3628683A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
EP3628682A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
EP3950776A4 (en) * | 2019-03-29 | 2023-01-04 | NOF Corporation | BRANCHED AND DEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE |
CN111939244A (zh) * | 2019-05-14 | 2020-11-17 | 阿莫生命科学有限公司 | 用于预防或治疗糖尿病并发症的药物组合物 |
KR102456958B1 (ko) | 2019-05-14 | 2022-10-21 | 강원대학교 산학협력단 | 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물 |
US20220401525A1 (en) * | 2021-06-16 | 2022-12-22 | Biocell Technology, Llc | Use of collagen compositions for increasing telomere length |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1176158A (en) * | 1981-08-27 | 1984-10-16 | Ronald E. Chance | Pharmaceutical formulations comprising human insulin and human c-peptide |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
FR2686759B1 (fr) | 1992-01-29 | 1994-04-22 | Sgs Thomson Microelectronics | Dispositif de regulation de puissance pour un haut-parleur de poste de telephone pendant une sonnerie . |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
SE520392C2 (sv) | 1996-09-27 | 2003-07-01 | Creative Peptides Sweden Ab C | Specifika peptider för behandling av diabetes mellitus |
US6410511B2 (en) * | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
GB9716790D0 (en) | 1997-08-07 | 1997-10-15 | Creative Peptides Sweden Ab | Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof |
US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
ATE399809T1 (de) | 1998-03-12 | 2008-07-15 | Nektar Therapeutics Al Corp | Verfahren zur herstellung von polymerkonjugaten |
DE122007000001I1 (de) * | 1999-01-14 | 2007-06-28 | Amylin Pharmaceuticals Inc | Neue exendin agonist Formulierungen und deren Verabreichung |
US6376470B1 (en) | 1999-09-23 | 2002-04-23 | Enzon, Inc. | Polymer conjugates of ara-C and ara-C derivatives |
US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
AU781839B2 (en) | 1999-12-22 | 2005-06-16 | Nektar Therapeutics | Sterically hindered derivatives of water soluble polymers |
WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
GB0022342D0 (en) | 2000-09-12 | 2000-10-25 | Creative Peptides Sweden Ab | Reduction of the electrocardiographic QT interval |
DE10055857A1 (de) | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
DE10055742B4 (de) | 2000-11-10 | 2006-05-11 | Schwarz Pharma Ag | Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen |
US6436386B1 (en) | 2000-11-14 | 2002-08-20 | Shearwater Corporation | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
TW593427B (en) | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
US7265186B2 (en) | 2001-01-19 | 2007-09-04 | Nektar Therapeutics Al, Corporation | Multi-arm block copolymers as drug delivery vehicles |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
ATE446971T1 (de) | 2001-09-07 | 2009-11-15 | Biocon Ltd | Verfahren zur synthese von insulinpolypeptid- oligomer-konjugaten und proinsulinpolypeptid- oligomer-konjugaten und verfahren zu deren synthese |
KR100948532B1 (ko) * | 2001-11-07 | 2010-03-23 | 넥타르 테라퓨틱스 | 분지형 중합체 및 그의 공액체 |
MXPA04004809A (es) * | 2001-11-20 | 2004-08-11 | Pharmacia Corp | Conjugados de hormona de crecimiento humana modificada quimicamente. |
GB0218970D0 (en) | 2002-08-14 | 2002-09-25 | Creative Peptides Sweden Ab | Fragments of Insulin c-peptide |
JP4764630B2 (ja) | 2002-09-09 | 2011-09-07 | ネクター セラピューティックス | 水溶性ポリマーアルカナール |
JP4412461B2 (ja) | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드-종결 중합체 |
US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
TR201907313T4 (tr) | 2003-05-23 | 2019-06-21 | Nektar Therapeutics | İki PEG zinciri içeren PEG türevleri. |
WO2005002597A1 (en) | 2003-07-02 | 2005-01-13 | Polycord, Inc. | Method for delivering polymerized therapeutic agent compositions and compositions thereof |
CN1852740B (zh) | 2003-09-17 | 2011-05-11 | 耐科塔医药公司 | 多支链聚合物的药物前体 |
GB0323979D0 (en) | 2003-10-13 | 2003-11-19 | Creative Peptides Sweden Ab | Therapeutic applications for c-peptide |
CN103045601B (zh) * | 2004-04-22 | 2015-04-01 | 雷加多生物科学公司 | 改良的凝血因子调节物 |
US8562965B2 (en) | 2004-05-03 | 2013-10-22 | Nektar Therapeutics | Polymer derivatives comprising an acetal or ketal branching point |
WO2005107815A2 (en) | 2004-05-03 | 2005-11-17 | Nektar Therapeutics Al, Corporation | Polymer derivatives comprising an imide branching point |
GB0412174D0 (en) * | 2004-06-01 | 2004-06-30 | Creative Peptides Sweden Ab | Degradation-resistant analogues of pro-insulin c-peptide |
JP2008531482A (ja) * | 2005-02-10 | 2008-08-14 | ノボ ノルディスク アクティーゼルスカブ | C末端がpeg化された成長ホルモン |
US20100216690A1 (en) * | 2005-03-18 | 2010-08-26 | Novo Nordisk A/S | Pegylated Single-Chain Insulin |
GB0511269D0 (en) | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
EP2412744B1 (en) | 2005-07-18 | 2014-01-22 | Nektar Therapeutics | Method for preparing branched functionalised polymers using branched polyol cores |
GB0601950D0 (en) | 2006-01-31 | 2006-03-15 | Creative Peptides Sweden Ab | Compositions and methods of treating diabetes |
JP4261531B2 (ja) | 2005-09-06 | 2009-04-30 | 株式会社Nrlファーマ | ラクトフェリン複合体及びその製造方法 |
KR101400105B1 (ko) * | 2006-07-25 | 2014-06-19 | 리폭센 테크놀로지즈 리미티드 | N-말단 폴리시알화 |
ES2542146T3 (es) * | 2006-07-31 | 2015-07-31 | Novo Nordisk A/S | Insulinas extendidas PEGiladas. |
GB0622818D0 (en) | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
RU2007137048A (ru) | 2007-10-05 | 2009-04-10 | Общество С Ограниченной Ответственностью "Концерн О3" (Ru) | Лекарственное средство для лечения и предупреждения осложнений при сахарном диабете |
US20110182946A1 (en) | 2008-03-17 | 2011-07-28 | Board Of Regents, The University Of Texas System | Formation of Nanostructured Particles of Poorly Water Soluble Drugs and Recovery by Mechanical Techniques |
US20110165112A1 (en) * | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of c-peptides |
WO2010033240A2 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
US8410049B2 (en) | 2009-10-28 | 2013-04-02 | Cebix | Methods and kits for preventing hypoglycemia |
WO2011081915A2 (en) | 2009-12-15 | 2011-07-07 | Cebix Inc. | Methods for treating erectile dysfunction in patients with insulin-dependent diabetes |
KR20130115086A (ko) | 2010-05-17 | 2013-10-21 | 세빅스 인코포레이티드 | 페길화된 c-펩티드 |
-
2011
- 2011-05-17 KR KR1020127031723A patent/KR20130115086A/ko not_active Application Discontinuation
- 2011-05-17 NZ NZ603399A patent/NZ603399A/en not_active IP Right Cessation
- 2011-05-17 MX MX2012013375A patent/MX2012013375A/es not_active Application Discontinuation
- 2011-05-17 CA CA2798518A patent/CA2798518A1/en not_active Abandoned
- 2011-05-17 WO PCT/US2011/036858 patent/WO2011146518A2/en active Application Filing
- 2011-05-17 US US13/109,522 patent/US8927488B2/en not_active Expired - Fee Related
- 2011-05-17 JP JP2013511302A patent/JP2013533217A/ja active Pending
- 2011-05-17 CN CN2011800350917A patent/CN103119055A/zh active Pending
- 2011-05-17 EP EP11784109.8A patent/EP2571896A4/en not_active Withdrawn
-
2012
- 2012-05-04 US US13/463,887 patent/US8691755B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20130115086A (ko) | 2013-10-21 |
US20120178676A1 (en) | 2012-07-12 |
EP2571896A2 (en) | 2013-03-27 |
EP2571896A4 (en) | 2014-01-08 |
CN103119055A (zh) | 2013-05-22 |
WO2011146518A9 (en) | 2012-04-19 |
US8927488B2 (en) | 2015-01-06 |
JP2013533217A (ja) | 2013-08-22 |
WO2011146518A2 (en) | 2011-11-24 |
CA2798518A1 (en) | 2011-11-24 |
WO2011146518A3 (en) | 2012-03-08 |
US20120220542A1 (en) | 2012-08-30 |
US8691755B2 (en) | 2014-04-08 |
NZ603399A (en) | 2014-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012013375A (es) | Peptido c pegilado. | |
SMT201600216B (it) | Ottaidropirrolo[3,4.c]pirroli disostituiti come modulatori del recettore di orexina | |
CA2851316C (en) | Genes and proteins for alkanoyl-coa synthesis | |
JO3026B1 (ar) | مستضادات ببتيد شبيه الجلوكاجون - 2 | |
IL219865A0 (en) | Acid salt forms of polymer-drug conjugates, compositions comprising the same, methods of producing the same and uses thereof | |
MX2012008983A (es) | Dulces basados en proteinas de guisante. | |
WO2010096394A3 (en) | Aldehyde-tagged protein-based drug carriers and methods of use | |
EP2401264A4 (en) | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | |
IT1395519B1 (it) | Pezzo composito, nonche' impiego del pezzo composito | |
WO2012090150A3 (en) | New cell-penetrating peptides and uses thereof | |
ZA201208076B (en) | Improvements in or relating to scanning ophthalmoscopes | |
ZA201200370B (en) | Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means | |
MX342171B (es) | Peptido o complejo peptidico que se une a integrina ?2 y metodos y usos que implican a los mismos. | |
IT1400545B1 (it) | Procedimento per la preparazione di tessuto biologico per protesi biologiche. | |
MY169650A (en) | Crystalline recombinant interferon with altered spatial configuration,three-dimensional structure and uses thereof | |
WO2011034659A3 (en) | Advantageous mu-opiate receptor peptide compounds | |
GB201220630D0 (en) | Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldtjakob disease or diabetes mellitus | |
IL219182A (en) | 2-Amino-3-Methyl-Hex-5 Anoic Acid and Its Use to Create Peptides such as Citricine | |
AP2011006040A0 (en) | Extracellular plant ferredoxin-like protein and uses thereof. | |
IT1403778B1 (it) | Veicolo trainato, particolarmente atto all'impiego agricolo o forestale | |
Szulc et al. | Clair de lune: mélodie/musique de Joseph Szulc; poésie de Paul Verlaine. | |
Wikars | Vedskalbaggar i Hamra nationalpark. Gävleborgs län | |
BRPI1014211A2 (pt) | "composição." | |
斉藤美佳子 | Take it easy! | |
Gupta | Degree M. Sc.--University of Toronto, 2009. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |